A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MK0683 in Patients With Advanced Cancer (0683-008)
- Registration Number
- NCT00750178
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Brief Summary
This study will evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of MK0683 in patients with advanced cancer.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 30
Inclusion Criteria
- Patients 18 years or older
- Must agree to consume high fat meal and agree to fasting conditions
- Limit alcohol consumption
Exclusion Criteria
- Patient has a history of drug or alcohol abuse within 5 years of start of study
- Patient is known to have HIV
- Patient has participated in another investigational study within 4 weeks of start of study
- Patient cannot stop taking certain medications or herbal remedies
- Patient will require immunologic, radiation, surgery, or chemotherapy during the study
- Patient requires frequent blood transfusions
- Female patient is pregnant or nursing
- Patient has an active Hepatitis B or C infection
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description A vorinostat (MK0683 ) MK0683
- Primary Outcome Measures
Name Time Method Safety, tolerability, and PK of MK0683 28 Days
- Secondary Outcome Measures
Name Time Method Urinary excretion of MK0683 28 days